Apr. 30 at 4:47 PM
$PFE one of the biggest cash generators in pharma still trading like a post-covid leftover
we’re talking ~
$50B+ annual revenue, ~
$15B+ operating cash flow, and a dividend yield around 5–6% - that’s not a broken business.
add a pipeline with multiple late-stage programs and a heavy push into oncology, and you’ve got a company that doesn’t need hype to work
sentiment is low, fundamentals aren’t - that gap doesn’t stay forever
